 Subjects in this trial will be eligible if they have recent evidence of hormone refractory disease D3 and either a have a positive bone scan or a positive CT scan with obvious soft tissue metastasis or lymph nodes 1 cm, with a PSA doubling time of 12 months, a total PSA of 5 mgml, and are asymptomatic; or b have a negative bone scan with any PSA doubling time, are asymptomatic, and are not a candidate for chemotherapy. 